You are here
Products
Glypican-3 [GPC3/863]
Product group: | Primary |
Monoclonal/ Polyclonal: | Monoclonal |
Clone: | GPC3/863 |
Host: | Mouse |
Isotype: | IgG1 |
Application: | Flow cytometry (FC), Immunocytochemistry (ICC),Immunofluorescence (IF), Immunohistochemistry (IHC) |
Application notes: | 50-200 |
Conjugation Type: | Unconjugated |
Lightchain type: | Kappa |
Reactivity: | Human, Rat |
General notes: | Localization: cytoplasm and membrane. |
Buffer: | Tris EDTA pH9.0 |
UNSPSC code: | 12352203 |
Glypican-3 (GPC3) is a member of the glypican family of glycosyl phosphatidylinositol-anchored cell-surface heparan sulfate proteoglycans. GPC3 is a tissue and serum biomarker for the early detection of hepatocellular carcinoma. The anti-GPC3 antibody has been used to assess GPC3 expression in malignant and non-malignant liver tissue samples and for quantitative ELISA detection of GPC3 concentration in the serum. Capurro et al. have shown that GPC3 is expressed at the protein level by immunohistochemistry in most cases of primary liver cancer including small tumors, but is undetectable in normal liver and benign hepatic lesions. In addition, the authors found that GPC3 is significantly elevated in the serum of a large proportion of patients with Primary Liver Cancer. (Shipping Cost: €200.00)
Glypican-3 [GPC3/863]
Glypican-3 (GPC3) is a member of the glypican family of glycosyl phosphatidylinositol-anchored cell-surface heparan sulfate proteoglycans. GPC3 is a tissue and serum biomarker for the early detection of hepatocellular carcinoma. The anti-GPC3 antibody has been used to assess GPC3 expression in malignant and non-malignant liver tissue samples and for quantitative ELISA detection of GPC3 concentration in the serum. Capurro et al. have shown that GPC3 is expressed at the protein level by immunohistochemistry in most cases of primary liver cancer including small tumors, but is undetectable in normal liver and benign hepatic lesions. In addition, the authors found that GPC3 is significantly elevated in the serum of a large proportion of patients with Primary Liver Cancer.
Alternative names: